Who
Susan Mahony
Director
Company insider
Files Form 4 as: Director, Axsome Therapeutics; Director, Assembly Biosciences; Director, Zymeworks; Director, Horizon Therapeutics Public Ltd Co; Director, Zymeworks; SVP & Pres., Lilly Oncology, Eli Lilly and.
In numbers
- Trades disclosed
- 137
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $13.5M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 1 Dec 2009
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K300 at $246.18 | filing |
| 10 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $74K300 at $246.18 | filing |
| 9 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K300 at $237.21 | filing |
| 9 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K300 at $237.21 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,429 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,429 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,721 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,166 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,429 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | ASMB Assembly Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,500 at $0.00 | filing |
| 21 Feb 2025filed 25 Feb 2025 | AXSM Axsome Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,312 at $0.00 | filing |
News
Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?AXSM · fool.com · 8 Oct 2026
0 headlines in the last 90 days name Susan Mahony; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.